The idea that led to the site-agnostic indication for Keytruda (pembrolizumab) came from the academic oncologists, who ended up defining the biologic mechanism of activity of this class of drugs.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe